E. Imre Et Al. , "SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.," Minerva endocrinology , 2021
Imre, E. Et Al. 2021. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.. Minerva endocrinology .
Imre, E., Gunhan, H. G., Erel, P., & Ustay, Ö., (2021). SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.. Minerva endocrinology .
Imre, EREN Et Al. "SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.," Minerva endocrinology , 2021
Imre, EREN Et Al. "SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.." Minerva endocrinology , 2021
Imre, E. Et Al. (2021) . "SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.." Minerva endocrinology .
@article{article, author={EREN İMRE Et Al. }, title={SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study.}, journal={Minerva endocrinology}, year=2021}